Johnson & Johnson reported its fifth straight quarter with revenue growth of at least 6%. This surge has come despite the loss of patent protection for Stelara. Compensating for the shortfall is Tremfya, which topped the $2 billion mark in sales in a quarter for the first time.
Source: FiercePharma
